PCM
INDP icon

Prelude Capital Management’s Indaptus Therapeutics INDP Stock Holding History

Prelude Capital Management’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11
Closed -$181K – 1883
2019
Q1 		$181K Sell
11
-2
-15% -$35K 0.01% 746
2018
Q4 		$220K Buy
+13
New +$177K 0.01% 686

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Prelude Capital Management's INDP Position: Q1 2020 in Review

Prelude Capital Management sold out of Indaptus Therapeutics (INDP) in Q1 2020, closing a stake of 3 shares — an estimated $3K sold.

Prelude Capital Management first reported a position in INDP in Q4 2018 and held it in 5 quarters. The position peaked at $890K in Q4 2018. 20 funds tracked by Wall St. Rank hold INDP as of Q1 2020.

  • Prelude Capital Management reported no remaining Indaptus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Prelude Capital Management sold 3 Indaptus Therapeutics shares in Q1 2020, an estimated $3K.
  • Prelude Capital Management first reported a position in Indaptus Therapeutics in Q4 2018 and held it in 5 quarters.
  • Prelude Capital Management's Indaptus Therapeutics position peaked at $890K in Q4 2018.
  • 20 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.